Role of Intravenous Tranexamic Acid in Immediate Breast Reconstruction with an Extended Latissimus Dorsi Flap: A Retrospective Cohort Study

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Background

The purpose of this study was to assess the impact of intravenous tranexamic acid (TXA) on postoperative drainage, laboratory parameters, and complications in patients undergoing immediate extended latissimus dorsi (ELD) flap breast reconstruction.

Methods

This retrospective cohort study included 82 patients who underwent immediate ELD flap breast reconstruction between January 2019 and May 2026. The TXA group (n = 42) received 1 g of intravenous TXA at the start of surgery after its routine adoption in July 2021; the control group (n = 40) underwent surgery before this date without TXA. Drainage, perioperative hemoglobin, hematocrit, and CRP levels, and postoperative complications were assessed using multivariable linear regression, with Cox regression as a complementary time-to-event analysis.

Results

After adjustment for potential confounders, TXA use was associated with a shorter drain duration (β = −1.85 days, 95% CI −3.09 to −0.61; p = 0.004) and lower total drainage volume (β = −131.5 mL, 95% CI −247.2 to −15.8; p = 0.027). The adjusted Cox model also showed previous drain removal in the TXA group (HR = 2.59, 95% CI: 1.50-4.46; p < 0.001). Hematoma was found in 0 patients in the TXA group and 6 patients in the control group (p = 0.011); this result is to be regarded as descriptive and hypothesis-generating.

Conclusion

This study provides some evidence that intravenous TXA reduces postoperative drainage and hematoma rates after immediate ELD flap breast reconstruction; however, prospective randomized studies are necessary to validate its safety profile and define its exact role.

Article activity feed